Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
Phase 3
Active, not recruiting
- Conditions
- MetastasisProstatectomyProstate Cancer
- Interventions
- Drug: Ferrotran® (Ferumoxtran-10)
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Saving Patients' Lives Medical B.V.
- Target Recruit Count
- 200
- Registration Number
- NCT04261777
- Locations
- 🇧🇪
Universitair Ziekenhuis Ghent, Gent, Belgium
🇩🇪Charité - Universitätsklinikum Berlin, Berlin, Germany
🇩🇪Vivantes Klinikum Am Urban, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath